Cancer Biotherapy and Radiopharmaceuticals
Editor-in-Chief: Martin W. Brechbiel, PhD
ISSN: 1084-9785 | Online ISSN: 1557-8852 | 10 Issues Annually | Current Volume: 38
Impact Factor: 3.632* *2021 Journal Citation Reports™ (Clarivate, 2022)
The definitive source for peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.